ESR1 and breast cancer: For this reason, in this study, we selected 335 patients with ER/PR+ and HER2− breast cancer to explore our new ER/PR+ and HER2− breast cancer prognostic model using classical clinicopathologic variables, called the extended Cox prognostic model.